SCHEMBL17548972

SCHEMBL17548972

CCCNCCN(CCNC)C(=O)CC

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.36
S1PR2 O95136 7/20 0.34
S1PR1 P21453 7/20 0.34
S1PR3 Q99500 7/20 0.34
S1PR4 O95977 6/20 0.34
S1PR5 Q9H228 1/20 0.34
REN P00797 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
PRMT3 O60678 1/20 0.32
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32
PRMT1 Q99873 1/20 0.32
PRMT8 Q9NR22 1/20 0.32
ANPEP P15144 1/20 0.31
KDM4A O75164 1/20 0.30
KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27003670 0.88 PRMT3 (0.40) ALDH1A1HPGDPRMT3CARM1PRMT6
SCHEMBL15459518 0.86 ALDH1A1 (0.44) ALDH1A1HPGDPRMT3CARM1PRMT6
SCHEMBL1834944 0.80 LMNA (0.38) ALDH1A1PRMT3CARM1PRMT6PRMT1
SCHEMBL23487563 0.78 ALDH1A1 (0.40) PAOXS1PR2S1PR1S1PR3S1PR4
SCHEMBL18947415 0.78 PRMT3 (0.32) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL6123949 0.78 PAOX (0.34) PAOXALDH1A1HPGDPRMT3CARM1
SCHEMBL23487565 0.77 ALDH1A1 (0.42) RENALDH1A1HPGD
SCHEMBL260446 0.76 ALDH1A1 (0.33) ALDH1A1PRMT3CARM1PRMT6PRMT1
SCHEMBL17548968 0.76 ALDH1A1 (0.41) ALDH1A1HPGDKDM4AKDM4C
SCHEMBL13657716 0.75 PAOX (0.39) PAOXALDH1A1ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9910190-B2 Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof NOVARTIS AG (CH) 2018-03-06 US disclosed
US-20170293050-A1 POLY(OXAZOLINE-CO-ETHYLENEIMINE)-EPICHLOROHYDRIN COPOLYMERS AND USES THEREOF ALCON INC. (CH) 2017-10-12 US disclosed
US-9720138-B2 Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof NOVARTIS AG (CH) 2017-08-01 US disclosed
US-20160061995-A1 POLY(OXAZOLINE-CO-ETHYLENEIMINE)-EPICHLOROHYDRIN COPOLYMERS AND USES THEREOF ALCON INC. (CH) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160061995-A1 POLY(OXAZOLINE-CO-ETHYLENEIMINE)-EPICHLOROHYDRIN COPOLYMERS AND USES THEREOF EPN1, PAM, LAGE3 PAOX 1117/4885S1PR2 4332/4885S1PR1 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.